We commenced to estimate the economic impact of salmeterol/‰uticasone combination (SFC) therapy compared to ‰uticasone propionate (FP) therapy for asthma control in Japanese patients. A Markov model withˆve health states, developed by Price in 2002, was used. 1-week transition probabilities among status of asthma management were obtained from literature and epidemiological data from public data base. Direct cost for treatment was estimated from Japan medical fee schedule. Cost and eŠectiveness were not discounted due to 12-week simulation by the model. Univariate sensitivity analyses were undertaken to examine the main variables aŠecting cost-eŠectiveness. Probabilistic analysis was also undertaken to discuss statistical argument and to provide information for decision-making. In this analysis, the model was run over a 12-week period of time using transition probabilities. The results showed that treatment with SFC resulted in a higher proportion of totally controlled weeks per patient than treatment with FP (65.0 vs. 49.5％; incremental eŠectiveness by 15.5％), and lower mean direct asthma management costs (¥168 702 vs. ¥227 820). Probabilistic sensitivity analysis, conducted to assess robustness of the above base case result, showed that in the 95％ of cases SFC was dominant (more eŠective and less costly) to FP. It suggested that SFC will be the most cost-eŠective therapy for asthma control. It would, however, be required to further evaluate cost-eŠectiveness of SFC in long-term observation.
In the diagram the horizontal axis represents the eŠect diŠerence between SFC and FP for example, and the vertical axis represents the cost diŠerence. The alternative (FP) could be the status quo or a competing programme. If point is in quadrants II or IV the choice between the programmes is clear. In quadrant II SFC is both more eŠective and less costly than FP. That is, it dominates FP. In quadrant IV the opposite is true. In quadrants I and III the choice depends upon the maximum cost-eŠectiveness ratio one is willing to accept (willingness to pay; WTP). 27) 
